Remission of psoriasis 13 years after autologous stem cell transplant.
Sung, Sarah M, and Alexa B Kimball. 2015. “Remission of Psoriasis 13 Years After Autologous Stem Cell Transplant.”. Cutis 95 (6): E7-8.
Search
Search results
410 results found
A measure of chronic quality of life predicts socioeconomic and medical outcomes in psoriasis patients.
Kim, G E, E Seidler, and A B Kimball. 2015. “A Measure of Chronic Quality of Life Predicts Socioeconomic and Medical Outcomes in Psoriasis Patients.”. Journal of the European Academy of Dermatology and Venereology : JEADV 29 (2): 249-54.
OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.
Kimball, Alexa B, Kenneth J Rothman, Gregory Kricorian, David Pariser, Paul S Yamauchi, Alan Menter, Craig F Teller, et al. 2015. “OBSERVE-5: Observational Postmarketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis Final 5-Year Results.”. Journal of the American Academy of Dermatology 72 (1): 115-22.
Psoriasis epidemiology: the interplay of genes and the environment.
Enamandram, Monica, and Alexa B Kimball. 2013. “Psoriasis Epidemiology: The Interplay of Genes and the Environment.”. The Journal of Investigative Dermatology 133 (2): 287-9.
Adverse Reactions to Biologics in Psoriasis.
Lockwood, Stephen J, Lisette M Prens, and Alexa B Kimball. 2018. “Adverse Reactions to Biologics in Psoriasis.”. Current Problems in Dermatology 53: 1-14.
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich, Kristian, Kim A Papp, Andrew Blauvelt, Stephen K Tyring, Rodney Sinclair, Diamant Thaçi, Kristine Nograles, et al. 2017. “Tildrakizumab versus Placebo or Etanercept for Chronic Plaque Psoriasis (reSURFACE 1 and ReSURFACE 2): Results from Two Randomised Controlled, Phase 3 Trials.”. Lancet (London, England) 390 (10091): 276-88.
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
Kimball, Alexandra B, Thomas Luger, Alice Gottlieb, Luis Puig, Roland Kaufmann, Enkeleida Nikaï, Baojin Zhu, et al. 2016. “Impact of Ixekizumab on Psoriasis Itch Severity and Other Psoriasis Symptoms: Results from 3 Phase III Psoriasis Clinical Trials.”. Journal of the American Academy of Dermatology 75 (6): 1156-61.
Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis.
Kimball, A B, A N Naegeli, E Edson-Heredia, C-Y Lin, C Gaich, E Nikaï, K Wyrwich, and G Yosipovitch. 2016. “Psychometric Properties of the Itch Numeric Rating Scale in Patients With Moderate-to-Severe Plaque Psoriasis.”. The British Journal of Dermatology 175 (1): 157-62.
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.
Kimball, A B, K A Papp, K Reich, M Gooderham, Q Li, N Cichanowitz, C La Rosa, and A Blauvelt. 2020. “Efficacy and Safety of Tildrakizumab for Plaque Psoriasis With Continuous Dosing, Treatment Interruption, Dose Adjustments and Switching from Etanercept: Results from Phase III Studies.”. The British Journal of Dermatology 182 (6): 1359-68.
Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28.
Papp, K A, K Reich, A Blauvelt, A B Kimball, M Gooderham, S K Tyring, R Sinclair, et al. 2019. “Efficacy of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Three Randomized Controlled Trials at Weeks 12 and 28.”. Journal of the European Academy of Dermatology and Venereology : JEADV 33 (6): 1098-1106.